Route of Sexual Exposure Is Independently Associated With Seropositivity to HPV-16 and HPV-18 Among Clients of an STI Clinic in the Netherlands

Heiligenberg, Marlies; Alberts, Catharina J.; Waterboer, Tim; Speksnijder, A.G.C.L.; Vries, Henry J. C. de; Pawlita, Michael; Loeff, Maarten F. Schim van der

doi:10.1093/infdis/jit295

Cited by 18 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies observed that HPV seropositivity was positively associated with type-specific anal HPV infection rather than with genital (penile) HPV infection [20]–[22]. Also, seropositivity was higher among HIV-positive than HIV-negative MSM [23].…”

Section: Introductionmentioning

confidence: 85%

See 1 more Smart Citation

Anal, Penile, and Oral High-Risk HPV Infections and HPV Seropositivity in HIV-Positive and HIV-Negative Men Who Have Sex with Men

et al. 2014

Self Cite

View full text Add to dashboard Cite

The effects of single or multiple concordant HPV infections at various anatomical sites on type-specific HPV seropositivity are currently unknown. In this cross-sectional study we assessed whether high-risk HPV infections at various anatomical sites (i.e., anal canal, penile shaft, and oral cavity), as well as concordant infections at multiple anatomical sites, were associated with type-specific seropositivity in HIV-positive and HIV-negative MSM.MSM aged ≥18 years were recruited in Amsterdam, the Netherlands (2010–2011). Baseline anal, penile, and oral samples were analyzed for HPV DNA and genotyped using a highly sensitive PCR and reverse line blot assay. Virus-like particle (VLP) based multiplex immunoassay was used to asses HPV-specific serum antibodies against L1 VLPs. The associations between HPV infections and type-specific seropositivity of seven high-risk HPV types (7-hrHPV: types 16, 18, 31, 33, 45, 52, 58) were estimated using logistic regression analyses with generalized estimating equations. We found that 86% of 306 HIV-positive MSM and 62% of 441 HIV-negative MSM were seropositive for at least one 7-hrHPV type. 69% of HIV-positive and 41% of HIV-negative MSM were infected with at least one 7-hrHPV type at the anus, penis, or oral cavity. In multivariable analyses, 7-hrHPV seropositivity was associated with type-specific anal (and not penile) 7-hrHPV infection, and did not significantly increase with a higher number of infected anatomical sites. Oral 7-hrHPV infection showed a positive, albeit non-significant, association with seropositivity. In conclusion, seropositivity among MSM appears to be largely associated with anal HPV infection, irrespective of additionally infected anatomical sites.

show abstract

Section: Introductionmentioning

confidence: 85%

“…If seroconversion does occur, antibodies may persist for many years [15]. Seropositivity is thought to be associated with persistent HPV infection, HPV viral load, and anatomical site of infection [13], [16]–[22].…”

Section: Introductionmentioning

confidence: 99%

Anal, Penile, and Oral High-Risk HPV Infections and HPV Seropositivity in HIV-Positive and HIV-Negative Men Who Have Sex with Men

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…The positive association of the increasing number of male anal sex LTP with the seropositivity of HPV is also consistent with previous studies [20, 35] and is likely to be explained by i) the increased probability of exposure to HPV types due to multiple sex partners, ii) the highest DNA prevalence of HPV infection and persistence in the anal canal of MSM, and iii) the anatomic site-specific immune response. Studies have shown that HPV infection is common in the anal canal, and its prevalence is higher among MSM than men who have sex with women (MSW) [35–37]. Recently, emerging evidence showed that HPV infection persists longer in the anal canal of MSM [38] which may explain the highest incidence of HPV-related anal cancers in MSM [39].…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundHuman papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Recently a 9-valent HPV (9vHPV) prophylactic vaccine was licensed. Seroprevalence prior to vaccine dissemination is needed for monitoring vaccine effectiveness over time. Few studies have assessed the seroprevalence of 9vHPV types in men.ObjectivesTo investigate the seroprevalence of 9vHPV vaccine types and associated risk factors among men residing in Brazil, Mexico, and the United States.MethodsSix hundred men were randomly selected from the HPV Infection in Men (HIM) Study. Archived serum specimens collected at enrollment were tested for antibodies against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52 and 58) using a glutathione S-transferase (GST) L1-based multiplex serologic assay. Socio-demographic, lifestyle and sexual behavior data at enrollment were collected through a questionnaire. Binomial proportions were used to estimate seroprevalence and logistic regression was used to examine factors associated with seropositivity of type-specific and grouped (i.e. 9vHPV, high-risk 9vHPV, low risk 9vHPV, and five-additional) HPV types.ResultsOverall, 28.3% of men were seropositive for at least one of the 9vHPV vaccine types, 14.0% for at least one of the seven high-risk types (16, 18, 31, 33, 45, 52 and 58) and 11.2% for at least one of the five high-risk types (31, 33, 45, 52 and 58) not included in the quadrivalent HPV vaccine, and 17.4% for at least one of the low-risk types (6/11). In multivariate analyses, odds ratios adjusted (AOR) for country of residence, age, marital status, smoking, number of anal sex lifetime partners, compared to men with no anal sex lifetime partners, men with ≥2 partners were more likely to be seropositive for grouped HPV [(9vHPV: AOR 2.52; 95% confidence interval (CI) 1.40–4.54), (high-risk 9vHPV: AOR 2.18; 95%CI: 1.05–4.50) and (low-risk 9vHPV: AOR 2.12; 95%CI: 1.12–4.03)], and individual HPV types 6, 16, 33 and 58 with AORs ranging from 2.19 to 7.36. Compared to men aged 18–30 years, men older than 30 years were significantly more likely to be seropositive for any high-risk 9vHPV, in addition to individual types 18 and 45; and compared to never smokers, current smokers were more likely to be seropositive to 9vHPV, low-risk 9vHPV and HPV 6. In contrast, married men were less likely to be seropositive to any high-risk 9vHPV and individual HPV types 18 and 31 when compared to single men.ConclusionsThese data indicate that exposure to the nine HPV types included in the 9vHPV vaccine is common in men and that seropositivity to 9vHPV vaccine types is associated with older age and the lifetime number of anal sex partners. Nine valent HPV vaccination of males and females has the potential to prevent HPV related diseases and transmission in both sexes.

show abstract

“…Generally, the cross-sectional correlation between detection of HPV DNA and type-specific antibodies is poor (9,26). However, recent data suggest that the anatomic site of HPV infection could influence seropositivity (12,27,28); mucosal (e.g., anal) infections might be more likely to elicit a humoral immune response than infections in keratinized epithelium (e.g., the penile shaft). In addition, it has been observed that persistent, rather than transient, HPV infection is associated with seroconversion (5,9,29).…”

Section: Discussionmentioning

confidence: 99%

HPV Seroconversion Following Anal and Penile HPV Infection in HIV-Negative and HIV-Infected MSM

Mooij

Landén

Klis

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Background: We assessed human papillomavirus (HPV) seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected men who have sex with men (MSM).Methods: MSM aged !18 years were recruited in Amsterdam, the Netherlands (2010-2011), and followed up semiannually. Antibodies against 7 high-risk HPV types in baseline and 12-month serum samples were tested using a multiplex immunoassay. Baseline, 6-, and 12-month anal and penile samples were tested for HPV DNA using the SPF 10 -PCR DEIA/LiPA 25 system. Statistical analyses were performed using logistic regression with generalized estimating equations.Results: Of 644 MSM included in the analysis, 245 (38%) were HIV-infected. Median age was 38 years for HIV-negative and 47 years for HIV-infected MSM (P < 0.001). Seroconversion against !1 of the 7 HPV types was observed in 74 of 396 (19%) HIV-negative and 52 of 223 (23%) HIV-infected MSM at risk (P ¼ 0.2). Incident [adjusted OR (aOR) 2.0; 95% confidence interval (CI), 1.1-3.4] and persistent (aOR 3.7; 95% CI, 1.5-9.5) anal HPV infections were independently associated with type-specific seroconversion in HIV-negative MSM. In HIVinfected MSM, there was a nonsignificant positive association between penile HPV infection at any time point and seroconversion (aOR 1.7; 95% CI, 0.9-3.2).Conclusions: Incident or persistent anal HPV infection was an independent determinant of seroconversion in HIV-negative MSM.Impact: Our data support that seroresponse may vary per anatomic site and that persistent HPV infections are more likely to elicit a detectable humoral immune response. Cancer Epidemiol Biomarkers Prev; 23(11); 2455-61. Ó2014 AACR.

show abstract

Route of Sexual Exposure Is Independently Associated With Seropositivity to HPV-16 and HPV-18 Among Clients of an STI Clinic in the Netherlands

Cited by 18 publications

References 11 publications

Anal, Penile, and Oral High-Risk HPV Infections and HPV Seropositivity in HIV-Positive and HIV-Negative Men Who Have Sex with Men

Anal, Penile, and Oral High-Risk HPV Infections and HPV Seropositivity in HIV-Positive and HIV-Negative Men Who Have Sex with Men

Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study

HPV Seroconversion Following Anal and Penile HPV Infection in HIV-Negative and HIV-Infected MSM

Contact Info

Product

Resources

About